Nomura Holdings Inc. Decreases Stock Holdings in DexCom, Inc. $DXCM

Key Points

• Nomura Holdings Inc. reduced its stake in DexCom, Inc. by 81.1%, selling 66,167 shares and holding only 15,396 shares after the transaction.
• Various institutional investors, including Horizon Investments and Wedbush Securities, raised their positions in DexCom, with institutional ownership reaching 97.75% of the company's stock.
• Recent analyst ratings for DexCom are predominantly positive, with a consensus of "Moderate Buy" and a price target averaging $99.89, suggesting expected growth in stock value.

Nomura Holdings Inc. trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 81.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,396 shares of the medical device company's stock after selling 66,167 shares during the quarter. Nomura Holdings Inc.'s holdings in DexCom were worth $1,051,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in DXCM. Golden State Wealth Management LLC lifted its stake in shares of DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock valued at $27,000 after purchasing an additional 264 shares during the period. Zions Bancorporation National Association UT acquired a new position in shares of DexCom during the first quarter worth about $27,000. Heck Capital Advisors LLC acquired a new position in DexCom during the fourth quarter worth about $38,000. Alpine Bank Wealth Management acquired a new position in shares of DexCom during the 1st quarter valued at about $40,000. Finally, Private Trust Co. NA raised its position in DexCom by 99.4% in the first quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock valued at $46,000 after purchasing an additional 335 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 500 shares of the company's stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $80.29, for a total transaction of $40,145.00. Following the transaction, the executive vice president directly owned 94,102 shares of the company's stock, valued at $7,555,449.58. This represents a 0.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Sadie Stern sold 1,466 shares of the company's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $88.99, for a total transaction of $130,459.34. Following the sale, the executive vice president owned 106,689 shares in the company, valued at $9,494,254.11. The trade was a 1.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,722 shares of company stock valued at $1,306,131. Corporate insiders own 0.32% of the company's stock.

DexCom Price Performance

NASDAQ DXCM traded down $2.66 during trading hours on Monday, reaching $77.86. The company's stock had a trading volume of 2,391,984 shares, compared to its average volume of 3,919,769. The stock has a market cap of $30.53 billion, a PE ratio of 54.03, a PEG ratio of 1.69 and a beta of 1.48. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The company's 50-day moving average is $81.58 and its two-hundred day moving average is $79.00. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.13 billion. During the same period in the previous year, the business earned $0.43 earnings per share. The company's revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. Analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on DXCM shares. William Blair raised DexCom to a "strong-buy" rating in a report on Thursday, July 31st. Oppenheimer cut shares of DexCom from an "outperform" rating to a "market perform" rating in a research report on Monday. Morgan Stanley increased their price target on DexCom from $82.00 to $89.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. Truist Financial started coverage on shares of DexCom in a report on Monday, June 16th. They issued a "buy" rating and a $102.00 price target on the stock. Finally, The Goldman Sachs Group began coverage on DexCom in a research report on Friday, May 30th. They set a "buy" rating and a $104.00 price target on the stock. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $99.89.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.